Novel Tumor-Specific ADC

About Precision Biologics

Precision Biologics is a private, clinical-stage biotech founded in 2014 and headquartered in Rockville, MD, with an additional office in Bethesda. The company's core asset is a proprietary library of patient tumor-derived cancer vaccines and antigens, originally developed by immunotherapy pioneer Dr. Ariel Hollinshead. This platform enables the discovery of novel, tumor-specific targets for the development of monoclonal antibodies and ADCs, positioning the company in the targeted oncology space with a focus on both therapeutics and companion diagnostics. Leadership is anchored by CEO Dr. Philip M. Arlen, who continues the scientific legacy of his father, Dr. Myron Arlen.

Therapeutic Areas